IN2014KN01341A - - Google Patents

Info

Publication number
IN2014KN01341A
IN2014KN01341A IN1341KON2014A IN2014KN01341A IN 2014KN01341 A IN2014KN01341 A IN 2014KN01341A IN 1341KON2014 A IN1341KON2014 A IN 1341KON2014A IN 2014KN01341 A IN2014KN01341 A IN 2014KN01341A
Authority
IN
India
Prior art keywords
satisfying
criteria
compositions
injectable
cyclodextrin
Prior art date
Application number
Other languages
English (en)
Inventor
Kirby Shawn Pasloske
Kai Lau
Sarah Jane Richardson
Amanda Aileen Willis
Original Assignee
Jurox Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904970A external-priority patent/AU2011904970A0/en
Application filed by Jurox Pty Ltd filed Critical Jurox Pty Ltd
Publication of IN2014KN01341A publication Critical patent/IN2014KN01341A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/14Quaternary ammonium compounds, e.g. edrophonium, choline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN1341KON2014 2011-11-29 2012-11-27 IN2014KN01341A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011904970A AU2011904970A0 (en) 2011-11-29 Pharmaceutical compositions
AU2012904962A AU2012904962A0 (en) 2012-11-09 Pharmaceutical compositions
PCT/AU2012/001452 WO2013078500A1 (fr) 2011-11-29 2012-11-27 Procédés de conservation de compositions pharmaceutiques injectables comprenant une cyclodextrine et un médicament hydrophobe

Publications (1)

Publication Number Publication Date
IN2014KN01341A true IN2014KN01341A (fr) 2015-10-16

Family

ID=48534526

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1341KON2014 IN2014KN01341A (fr) 2011-11-29 2012-11-27

Country Status (18)

Country Link
US (3) US9492552B2 (fr)
EP (2) EP2785352B1 (fr)
JP (2) JP5819005B2 (fr)
KR (1) KR101922752B1 (fr)
CN (2) CN103998046B (fr)
AR (1) AR089004A1 (fr)
AU (1) AU2012268889B2 (fr)
BR (1) BR112014012985B1 (fr)
CA (1) CA2852716C (fr)
DK (1) DK2785352T3 (fr)
ES (1) ES2784629T3 (fr)
HR (1) HRP20200567T1 (fr)
IL (1) IL232860B (fr)
IN (1) IN2014KN01341A (fr)
SG (2) SG10201506273PA (fr)
TW (1) TWI552770B (fr)
WO (1) WO2013078500A1 (fr)
ZA (1) ZA201402895B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
WO2013112605A2 (fr) 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Formulation de stéroïde neuroactif et procédés de traitement des troubles de snc
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
JP6180241B2 (ja) * 2013-08-29 2017-08-16 学校法人同志社 シクロデキストリン誘導体及び医薬組成物
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
WO2015086729A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs glp-1/gip
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
EP3294953B1 (fr) * 2015-04-01 2019-07-24 International Dioxcide Inc. Composition stabilisée pour lutte contre les odeurs et déshydratation renforcée combinées
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105044A1 (es) * 2015-06-18 2017-08-30 Sage Therapeutics Inc Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
KR101718733B1 (ko) * 2015-08-21 2017-03-22 국제약품 주식회사 레바미피드의 가용화 방법 및 이에 의해 제조된 안구건조증 치료용 액제
NL2015865B1 (en) * 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
ES3007857T3 (en) * 2017-05-10 2025-03-20 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
CN110215430A (zh) * 2018-03-02 2019-09-10 刘力 新型可注射的硝酸甘油药物组合物
CN110464846B (zh) * 2018-05-11 2023-04-18 南京清普生物科技有限公司 一种美洛昔康组合物、制剂及其制备方法与应用
KR102141826B1 (ko) * 2018-10-05 2020-08-07 건국대학교 산학협력단 양이온성 베타 시클로덱스트린 올리고머를 이용한 외부 pH 자극 반응형 자가치유성 하이드로젤
US20220000797A1 (en) * 2018-11-07 2022-01-06 (Bika Biotechnology (Guangzhou) Co., Ltd) Clear propofol injection and preparation method therefor
CA3129648A1 (fr) * 2019-02-15 2020-08-20 Saol International Limited Formulations injectables comprenant un phenol et une cyclodextrine, et utilisations connexes
EP3725298A1 (fr) 2019-04-16 2020-10-21 Faes Farma, S.A. Compositions pharmaceutiques stables et préservées de bilastine
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
EP3766475A1 (fr) 2019-07-15 2021-01-20 OP-Hygiene IP GmbH Lingettes
FR3117337B1 (fr) * 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
CN115487138A (zh) * 2021-06-18 2022-12-20 北京万全德众医药生物技术有限公司 别孕烯醇酮注射剂及其制备方法
KR102848049B1 (ko) 2022-02-14 2025-08-20 주식회사 아크 파라벤계 보존제의 안정성 증진용 조성물 및 이를 포함하는 보존제

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728509A (en) 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
JPH06293638A (ja) * 1993-04-06 1994-10-21 Lion Corp 安定なビタミンa類点眼剤
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
JP3934705B2 (ja) * 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP2002523475A (ja) 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
AUPQ633900A0 (en) 2000-03-20 2000-04-15 Jurox Pty Ltd Anaesthetic composition
IN187686B (fr) 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
JP2003089632A (ja) * 2001-09-17 2003-03-28 Otsuka Pharmaceut Factory Inc 注射用水性製剤
US20050239746A1 (en) 2002-02-01 2005-10-27 Penkler Lawrence J Pharmaceutical composition
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
JP4275394B2 (ja) * 2002-12-05 2009-06-10 株式会社大塚製薬工場 注射用シロスタゾール水性製剤
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
US6969706B1 (en) 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
JP5577021B2 (ja) 2005-02-17 2014-08-20 アボット・ラボラトリーズ 動物における障害を治療および予防するための薬剤組成物の経粘膜投与
WO2007062339A2 (fr) 2005-11-18 2007-05-31 Astrazeneca Ab Formulations liquides
EP2373166A4 (fr) * 2008-11-15 2014-11-05 Rib X Pharmaceuticals Inc Compositions antimicrobiennes
CA2786762C (fr) * 2010-01-21 2017-12-05 Goodchild Investments Pty Ltd Formulation anesthesique

Also Published As

Publication number Publication date
IL232860A0 (en) 2014-07-31
ZA201402895B (en) 2015-11-25
US9492552B2 (en) 2016-11-15
EP2785352B1 (fr) 2020-03-11
JP6095707B2 (ja) 2017-03-15
BR112014012985A2 (pt) 2017-06-13
KR101922752B1 (ko) 2018-11-27
EP2785352A4 (fr) 2015-07-29
ES2784629T8 (es) 2020-11-23
US20170014428A1 (en) 2017-01-19
US20140336163A1 (en) 2014-11-13
AR089004A1 (es) 2014-07-23
CN107261152A (zh) 2017-10-20
BR112014012985B1 (pt) 2020-05-12
CA2852716A1 (fr) 2013-06-06
JP2015145364A (ja) 2015-08-13
SG11201401597TA (en) 2014-05-29
EP2785352A1 (fr) 2014-10-08
CN107261152B (zh) 2022-03-04
CN103998046A (zh) 2014-08-20
TW201328721A (zh) 2013-07-16
DK2785352T3 (da) 2020-05-25
CN103998046B (zh) 2021-04-06
US20190125762A1 (en) 2019-05-02
CA2852716C (fr) 2015-11-17
NZ706101A (en) 2016-03-31
KR20140113629A (ko) 2014-09-24
SG10201506273PA (en) 2015-09-29
IL232860B (en) 2019-10-31
WO2013078500A1 (fr) 2013-06-06
AU2012268889A1 (en) 2013-06-13
JP2014533703A (ja) 2014-12-15
AU2012268889B2 (en) 2013-12-19
US20230293550A1 (en) 2023-09-21
TWI552770B (zh) 2016-10-11
EP3446692A1 (fr) 2019-02-27
US12303519B2 (en) 2025-05-20
NZ624592A (en) 2015-07-31
HRP20200567T1 (hr) 2020-06-26
ES2784629T3 (es) 2020-09-29
JP5819005B2 (ja) 2015-11-18
US10188664B2 (en) 2019-01-29
HK1198325A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
IN2014KN01341A (fr)
UY35907A (es) Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmaceuticas que las contienen, así como su uso para la preparación de medicamentos
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
MX362838B (es) Composiciones farmacéuticas de liberación prolongada para disuadir el abuso de opioides que comprenden un plastómero, un elastómero y un plastificante delicuescente.
MX363185B (es) Composición sinérgica para la protección de cultivos agrícolas y su uso.
IN2014DN06529A (fr)
WO2014194195A3 (fr) Polymères à base de cyclodextrine destinés à une administration thérapeutique
BR112016009669A8 (pt) produtos farmacêuticos, método para tratar câncer e uso de um composto
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
HK1201828A1 (en) Treatment regimens using multiple pharmaceutical agents
CO6311057A2 (es) Composicion de nisina liquida
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
EP2852395A4 (fr) Complexes améliorés et compositions contenant de la curcumine
MX341220B (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas.
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
EP2987786A4 (fr) Dérivé d'amidopyridinol ou sel pharmaceutiquement acceptable correspondant et composition pharmaceutique le comprenant comme constituant actif
HK1206621A1 (en) Formulations comprising idebenone, n-acetyl-s-farnesyl-l-cysteine and ergothioneine and uses thereof
WO2013192517A3 (fr) Composés destinés au traitement de maladies infectieuses
EP2877196A4 (fr) Ompa et asp14 dans des compositions de vaccin et en tant que cibles de diagnostic
MX371349B (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
GR1008234B (el) Παρεντερικο σκευασμα ενος αντιμυκητιασικου παραγοντα τριαζολης και μεθοδος για την παρασκευη αυτου
BR112013004714A2 (pt) "combinações de inibidores de hdac com fármacos de trombocitopenia e seus usos"